SCHEMBL12822337

SCHEMBL12822337

O=C(O)c1cccc(Cn2c(=O)[nH]c(=O)c3ccc(Cl)cc32)c1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.65
CCR2 P41597 1/20 0.58
HDAC6 Q9UBN7 4/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC1 Q13547 2/20 0.50
PDE5A O76074 1/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
MALT1 Q9UDY8 1/20 0.47
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PLA2G4A P47712 1/20 0.45
FOLH1 Q04609 2/20 0.45
PGR P06401 2/20 0.45
PLA2G10 O15496 1/20 0.44
MRGPRX4 Q96LA9 2/20 0.44
AR P10275 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12822453 0.91 CCR2 (0.61) MAT2ACCR2HDAC6HDAC8HDAC1
SCHEMBL12822485 0.86 HDAC8 (0.47) MAT2ACCR2HDAC6HDAC8HDAC1
SCHEMBL12822362 0.86 HDAC8 (0.64) MAT2ACCR2HDAC6HDAC8HDAC1
SCHEMBL30417796 0.85 FOLH1 (0.60) MAT2ACCR2HDAC6HDAC8KMT2A
SCHEMBL29568679 0.85 FOLH1 (0.60) MAT2ACCR2HDAC6HDAC8KMT2A
SCHEMBL12822199 0.85 FOLH1 (0.60) MAT2ACCR2HDAC6HDAC8KMT2A
SCHEMBL15421288 0.80 HDAC6 (0.78) MAT2ACCR2HDAC6HDAC8HDAC1
SCHEMBL12822194 0.80 HDAC8 (0.67) MAT2ACCR2HDAC6HDAC8HDAC1
SCHEMBL12822173 0.79 HDAC8 (0.64) MAT2ACCR2HDAC6HDAC8HDAC1
SCHEMBL12822103 0.79 HDAC8 (0.48) CCR2HDAC6HDAC8HDAC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2022-06-14 US disclosed
US-20190270732-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2019-09-05 US disclosed
EP-2709990-B1 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer IMPACT THERAPEUTICS INC (CN) 2019-06-12 EP disclosed
US-10316027-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2019-06-11 US disclosed
US-20180215741-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS INC (CN) 2018-08-02 US disclosed
US-9926304-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2018-03-27 US disclosed
US-20160237070-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2016-08-18 US disclosed
US-9290460-B2 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2016-03-22 US disclosed
EP-2709990-A1 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics, Inc. (CN) 2014-03-26 EP disclosed
US-20140023642-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2014-01-23 US disclosed
WO-2012130166-A1 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF IMPACT THERAPEUTICS, INC. (CN) 2012-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270732-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAT2A 3941/4885CCR2 1866/4885HDAC6 610/4885
US-10316027-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof PARP1, PARP11, PARP3 MAT2A 3895/4885CCR2 1721/4885HDAC6 542/4885
US-20160237070-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAT2A 3941/4885CCR2 1866/4885HDAC6 610/4885
US-20180215741-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAT2A 3895/4885CCR2 1721/4885HDAC6 542/4885
US-11358955-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof PARP1, PARP11, PARP3 MAT2A 3941/4885CCR2 1866/4885HDAC6 610/4885
US-20140023642-A1 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof PARP1, PARP11, PARP3 MAT2A 3909/4885CCR2 1776/4885HDAC6 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.